Company News: Eisai and Arena Pharmaceuticals

Share this article:
Japanese drug firm Eisai made a bet on obesity last week, signing a multi-million dollar deal with Arena Pharmaceuticals for the right to sell Arena's lorcaserin weight-loss pill, if approved. The deal includes a $50-million upfront, another $160 million based on development and approval milestones and a $1.16 billion, one-time payment that may follow based on annual sales. Eisai's timing was a bit surprising considering lorcaserin doesn't face an FDA panel until September and a decision until late October. Two other developers of diet pills are hoping for FDA approval, Orexigen for Contrave and Vivus for Qnexa, and both are seeking pharmaceutical partnerships. FDA is set to decide on Contrave in December. Qnexa faces an advisory panel July 15, and the FDA is scheduled to rule on the drug in October.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.